Radiopharmaceutical manufacturer Cyclotek and the University of Melbourne have signed a Strategic Partnership Agreement to set up a new research facility to support the advancement of cutting-edge cancer targeting technology.
The agreement is aimed at facilitating workforce development and the translation of radiopharmaceutical innovation to the commercial market.
The radiopharmaceutical research and development laboratory will be located at the University’s Parkville campus and will foster the development of medical radioisotope technologies and molecular targeting systems, which are currently being used in clinical trials to diagnose and treat cancer and neurological disease.
The facility will feature several purpose-built spaces including a molecular characterisation and quality control laboratory. This infrastructure will enable academic researchers, local biotechnology and international pharmaceutical companies to develop radiolabelling and quality control methods for their novel radiopharmaceutical assets and manufacture these for successful progression through early-phase clinical trials.
Professor Paul Donnelly, Richard Robson Chair of Chemistry at the University of Melbourne said: “This initiative represents an excellent opportunity to build research capacity in the chemical sciences and chemical manufacturing in an environment that will maximise dynamic interactions between University of Melbourne researchers and industry.”
University of Melbourne Dean of Science Professor Moira O’Bryan said: “This development will provide a world-class environment for radiopharmaceutical research and development, and undoubtedly other areas of research. This is a brilliant example of how clever chemistry improves the lives of Australians.”
Cyclotek’s Innovation and Partnerships Manager Sam Graf explained: “Fundamentally, the purpose of this partnership is to improve the accessibility of radiopharmaceuticals to enhance patient outcomes, which is Cyclotek’s primary mission. Our partnerships with the University of Melbourne promise to unlock new education and training opportunities while fostering a robust industry-academic partnership for the growth of the radiopharmaceutical industry.”
The development is supported by funding from the Australian Government. The funding has been instrumental in supporting this project, which will enable Cyclotek to better cater for radiopharmaceutical research and early phase translation of novel precision medicines. Cyclotek thanks the Australian Government for their contribution to this project.
The facility, which is being designed and delivered by the Cyclotek team, led by Joshua Seale and Dr Mark Frazzetto, in partnership with the University of Melbourne, is expected to be complete by mid-2025.
For further information, please contact: Mr Greg Santamaria – enquiries@cyclotek.com
Cyclotek is a global leader and innovator in the radiopharmaceutical industry. We are dedicated to providing radiopharmaceuticals of the highest quality and reliability, manufactured in compliance with rigorous global standards. Our mission is to ensure healthcare providers have the best tools available for precise diagnostics and therapies, ultimately improving patient care and outcomes.
At the heart of Cyclotek is a steadfast commitment to our customers. We understand that their needs and growth aspirations are central to our operations, and we work relentlessly to support them in every possible way. From cutting-edge manufacturing facilities to unparalleled customer service, every aspect of our business is designed with this commitment in mind.
We are more than just a manufacturing company; we are an innovation hub, continuously driving advancements in the radiopharmaceutical field. We believe in the transformative power of innovation, and we are dedicated to pushing boundaries, challenging norms, and pioneering breakthroughs.
Above all, Cyclotek stands for quality, reliability, customer focus, and innovation. Our customers, their patients, and the radiopharmaceutical industry as a whole can depend on our commitment to these values as we strive to make a positive impact on healthcare across the globe.
As a place of discovery and enquiry, the University of Melbourne’s purpose is to benefit society through the transformative impact of education and research.
Established in 1853, it is one of Australia’s oldest universities and the first in Victoria. Today, the University’s vibrant community comprises over 53,000 students, including 45 per cent international students from more than 150 countries. Our students are supported by over 10,000 academic and professional staff, who play a vital role in fulfilling the University’s mission. The diversity of experience, backgrounds and perspectives of all members of our community enriches the fabric of our University.
As a leading research-intensive university, our dual purposes of education and research are reflected in the experience we offer our students. Our educational approach encourages students to explore their passions and foster deep expertise in their chosen fields. We nurture a culture of curiosity and creativity, providing students with the opportunity to learn from academics and researchers at the forefront of their respective disciplines.
[contact-form-7 id=”714″ title=”Update Form”]
